Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection against Toxoplasma gondii Challenge Infection

Recombinant vaccinia viruses (rVVs) are attenuated viruses and are widely utilized as vectored vaccine platforms against numerous diseases. However, the protective efficacy of these rVV vaccines against Toxoplasma gondii and the resulting mucosal immunity has not been thoroughly assessed. Here, rVVs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Keon-Woong, Chu, Ki-Back, Kang, Hae-Ji, Kim, Min-Ju, Eom, Gi-Deok, Quan, Fu-Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878533/
https://www.ncbi.nlm.nih.gov/pubmed/35214611
http://dx.doi.org/10.3390/vaccines10020152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878533/
https://www.ncbi.nlm.nih.gov/pubmed/35214611
http://dx.doi.org/10.3390/vaccines10020152

Ejemplares similares